Skip to content


  • Meeting abstract
  • Open Access

Allergic diseases of the skin and drug allergies – 2017. Rapid desensitization for delayed reactions to chemotherapy and monoclonal antibodies

  • 1,
  • 1,
  • 1,
  • 1 and
  • 2
World Allergy Organization Journal20136:388

  • Published:


  • Corticosteroid
  • Infliximab
  • Paracetamol
  • Hypersensitivity Reaction
  • Biological Agent


Drug desensitization is the induction of temporary clinical unresponsiveness todrug antigens to which patients have presented severe hypersensitivity reactions (HSR). Rapid desensitization in patients suffering immediate hypersensitivity reactions with chemotherapeutic agents and monoclonal antibodies have been widely described and have shown to be successful. Non-immediate hypersensitivity reactions with other drugs have usually required desensitization with several days’ protocols to achieve total doses.


Thirty-eight desensitization procedures were performed in 5 patients with a 12-13 step, 6-hour protocol. All patients had developed a delayed maculopapular rash with the use of chemotherapeutic and/or biological agents. Three patients were pretreated with corticosteroids, paracetamol and antihistamines before each desensitization procedure.


All the 38 desensitizations undertaken were successfully completed (25 with Temozolamide, 4 with Bendamustine, 4 with Rituximab and 5 with Infliximab). We observed HSR during 8 (21%) of desensitizations, including 5 inmediate exantema and 3 delayed local macular exantema. Two patients were treated with corticosteroids and anti-histamines after the desensitization protocol to avoid more delayed HSR.


Rapid desensitization protocols are safe and effective in getting over delayed HSR to chemotherapeutic and monoclonal antibodies and allow patients with severe diseases to continue their treatment.

Authors’ Affiliations

Allergy Service, Hospital Universitario De Guadalajara, Guadalajara, Spain
Allergy Servicce, Hospital General De Ciudad Real, Ciudad Real, Spain


© Vega Castro et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.